Drug Trial Radar · NCT07870889
Vortosiran in Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Jul 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Ribocure Pharmaceuticals ABIndustry
- Sponsor type
- Industry
- Collaborators
- Link Medical Research AB
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF. The trial consists of three groups including 50 participants each. The participants will be randomized to either the low dose group or the high dose group receiving vortosiran or to the group receiving apixaban. The treatment will be open-label for vortosiran vs apixaban. The vortosiran dose will be blinded to patients and investigators. Both the low- and the high-dose group will receive two doses of vortosiran, the first dose at Day X and the second at Day Y. After 24 weeks, at the end of the vortosiran treatment period, the participants will start an open-label part of the trial and will be switched to standard-of-care apixaban treatment until Week 64 (End of Trial; EOT). Participants in the open-label apixaban arm will receive apixaban as standard of care during the entire trial.
Conditions
- Non-valvular Atrial Fibrillation (AF)
Interventions
VortosiranDrug
Vortosiran, active drug
VortosiranDrug
Vortosiran, active drug
ApixabanDrug
Comparator, active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary objectiveTime frame: At week 16
- Primary endpointTime frame: At week 16
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Frederiksberg Hospital
Frederiksberg, Denmark
Herlev-Gentofte
Herlev, Denmark
Sykehuset Østfold Kalnes Kardiologisk
Grålum, Norway
Akershus Universitetssykehus Ahus Kardiologisk
Lørenskog, Norway
EMC Silesia spółka z ograniczoną odpowiedzialnością
Katowice, Poland
Centrum Medyczne Vitamedicum
Krakow, Poland
Balsam Medica Sp z o.o.
Raszyn, Poland
Aidport Clinical Trial Hospital
Skorzewo, Poland
Centrum Medyczne LUX MED
Warsaw, Poland
Centrum Badań Klinicznych
Wroclaw, Poland
Centrum Medyczne Oporów
Wroclaw, Poland
Pracownia Badan Klinicznych Salus
Wroclaw, Poland
Danderyds Sjukhus - Hjärtmottagningen
Danderyd, Sweden
SUS Lund, Department of Cardiology
Lund, Sweden
Södersjukhuset, Department of Cardiology
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.